FDA approves Protagonist/Takeda Mimrylo for polycythemia vera

The FDA approved Mimrylo, a novel therapy from Protagonist and Takeda, for polycythemia vera, a rare blood cancer. This marks a new treatment option in a niche oncology space, though commercial impact is limited by the disease's rarity. The approval is a company-specific catalyst rather than a systemic market signal.